A number of potential targeting strategies exist to block CAF-mediated tumour support, including inhibition of CAF cell-surface proteins (such as the anti-FAP antibody Sibrotuzumab169), blocking CAF activation or by targeting CAF-tumour signalling159. This evidence concerns the gene FAP and neoplasm.